![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PATE2 |
Gene summary for PATE2 |
![]() |
Gene information | Species | Human | Gene symbol | PATE2 | Gene ID | 399967 |
Gene name | prostate and testis expressed 2 | |
Gene Alias | C11orf38 | |
Cytomap | 11q24.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6UY27 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
399967 | PATE2 | HCC1 | Human | Liver | HCC | 3.29e-07 | 5.92e-01 | 0.5336 |
399967 | PATE2 | HCC2 | Human | Liver | HCC | 2.33e-16 | 1.22e+00 | 0.5341 |
399967 | PATE2 | HCC5 | Human | Liver | HCC | 3.25e-10 | 8.29e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PATE2 | insertion | In_Frame_Ins | novel | c.76_76+1insCAGTCACTATGCTGGAAGAAGTAATTGGTCCTGAAC | p.Ala26_Thr27insValThrMetLeuGluGluValIleGlyProGluPro | p.A26_T27insVTMLEEVIGPEP | Q6UY27 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
PATE2 | SNV | Missense_Mutation | novel | c.256G>A | p.Asp86Asn | p.D86N | Q6UY27 | protein_coding | tolerated(0.2) | benign(0.03) | TCGA-MY-A913-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PATE2 | SNV | Missense_Mutation | c.138N>T | p.Met46Ile | p.M46I | Q6UY27 | protein_coding | deleterious(0.04) | benign(0.359) | TCGA-A6-4107-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5 | SD | |
PATE2 | deletion | Frame_Shift_Del | c.108delA | p.Lys36AsnfsTer11 | p.K36Nfs*11 | Q6UY27 | protein_coding | TCGA-DM-A1HA-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |||
PATE2 | SNV | Missense_Mutation | c.335N>A | p.Gly112Glu | p.G112E | Q6UY27 | protein_coding | deleterious(0) | possibly_damaging(0.451) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
PATE2 | SNV | Missense_Mutation | novel | c.180N>T | p.Glu60Asp | p.E60D | Q6UY27 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
PATE2 | SNV | Missense_Mutation | novel | c.113N>G | p.His38Arg | p.H38R | Q6UY27 | protein_coding | deleterious(0.04) | possibly_damaging(0.833) | TCGA-37-A5EM-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PATE2 | insertion | Frame_Shift_Ins | novel | c.271_272insAGAGCAAAATTCA | p.Gly91GlufsTer16 | p.G91Efs*16 | Q6UY27 | protein_coding | TCGA-H7-8502-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | SD | ||
PATE2 | SNV | Missense_Mutation | rs748478418 | c.216N>A | p.Met72Ile | p.M72I | Q6UY27 | protein_coding | tolerated(0.11) | benign(0.007) | TCGA-CH-5761-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD |
PATE2 | SNV | Missense_Mutation | novel | c.251G>C | p.Cys84Ser | p.C84S | Q6UY27 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |